Bactiguard and German company Schülke & Mayr GmbH (schülke) have signed an exclusive distribution agreement for Bactiguard’s range of wound care solutions to German hospitals. schülke is one of the leading global manufacturers and distributors within infection prevention and hygiene solutions.
The collaboration enables schülke to complement its comprehensive product range of antiseptic and wound care products with Bactiguard’s hypochlorous acid-based portfolio.
“We are excited about the collaboration with schülke and believe our mutual goal of preventing infections is an excellent foundation for the future. Together with schülke we aim to further develop the market for products based on hypochlorous acid – with the ultimate goal of improving patient safety and well-being”, says Peter Rådqvist, Global Head of Sales at Bactiguard.
Hypochlorous acid is an antimicrobial substance that reduces the risk of infection and promotes wound healing. It is present in the human immune system and has a favourable biocompatilibity profile, meaning it is not harming human cells. The German launch is scheduled for Q3 2021.
Headquartered outside Hamburg, Germany, schülke is a pioneer in infection prevention and hygiene solutions with more than 130 years of experience in providing disinfection and wound care products. The company is represented in more than 100 countries and has more than 1,000 employees globally. The agreement means that schülke will distribute Bactiguard’s wound care solutions to German hospitals.
Bactiguard’s new wound care range
Bactiguard’s wound care range is a non-alcoholic, pH-neutral and water-based product line that can be used by both children and adults. The products are biocompatible, which means that they are not irritating to the skin or other tissue. They contain hypochlorous acid, the same substance as the body’s immune cells use in their defence against infectious organisms. The products neither smell strongly or sting, but effectively kill most virus, bacteria and fungi that cause infections, including the new coronavirus SARS-CoV-2.1
For further information, please contact:
Petra Kaur, Chief Marketing and Communication Officer, mobile +46 79 304 96 36
1. In collaboration with the Swedish Veterinary Institute (SVA), tests have been carried out with Hydrocyn aqua on a virus culture of the new Coronavirus (SARS-CoV-2) that causes covid-19. The results showed that 99.98% of the virus particles were inactivated – and thus not contagious.
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard’s coating are market leaders in the USA and Japan through our licensing partner BD.
Bactiguard’s product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body’s immune cells use in their defence against infectious organisms.
Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas.
Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com
The company is a leader in the field of infection prevention and hygiene solutions for more than 130 years. Schülke & Mayr GmbH develops, produces and distributes antiseptics for wound care, disinfectants and medical and cosmetic skin care products. The company offers its customers innovative products, solutions and services in the professional healthcare business, over the counter (OTC) and hygiene solutions for the pharma sector. schülkes mission is to protect lives worldwide and thereby actively contributes to patient safety. The company is headquartered in Germany, employs more than 1,000 people worldwide and sells its products in more than 100 countries. schülke is represented by 15 subsidiaries and operates production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma). www.schuelke.com